Adidas CEO Kasper Rorsted expressed doubts that the efforts by the COP26 United Nations Climate Change Conference of Parties in Glasgow would work without the involvement of China, the world's largest emitter.
Rorsted believes China's absence will hamper COP26, saying that "nothing works without China".
The key summit, which ends November 12, brings together global leaders with the aim of accelerating action against climate change and limiting the rise in global temperatures.
But Rorsted said the first step should have been to talk to 10 countries first.
Several nations have made pledges on reversing deforestation, cutting methane emissions, and transition from the use of coal to cleaner forms of energy.
Chinese leader Xi Jinping did deliver a statement urging all parties to "take stronger actions to jointly tackle the climate challenge."
China said it aims to cut greenhouse gas emissions to "net-zero" by 2060.
Rorsted also criticized the use by delegates of over 400 private jets to travel to Glasgow, saying: "They don't seem to have heard of an exemplary position."


Nomura Upgrades PDD Holdings to Buy, Calls Stock Too Cheap to Ignore
Merck's $6 Billion Bid for Terns Pharma Signals Bold Oncology Push
Oil Prices Climb as Iran Reviews U.S. Peace Proposal Amid Middle East Tensions
Iran Allows Oil Tankers Through Strait of Hormuz Amid U.S. Negotiations
NASDAQ Tech Selloff: Correction or Collapse? What Analysts Are Saying
An unexpected anomaly was found in the Pacific Ocean – and it could be a global time marker
How is Antarctica melting, exactly? Crucial details are beginning to come into focus
Fertile land for growing vegetables is at risk — but a scientific discovery could turn the tide
How America courted increasingly destructive wildfires − and what that means for protecting homes today
SpaceX IPO Filing Expected This Week as Valuation Could Surpass $75 Billion
ECB Eyes Rate Hike Amid Iran Conflict-Driven Energy Price Surge
Burkina Faso and Mali’s fabulous flora: new plant life record released
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal 



